Metabolic Studies
Retatrutide
Triple-agonist GLP-1/GIP/glucagon research compound.
Specifications
- Formula
- C71H110N18O19
- Molecular Weight
- 1510.77 g/mol
- Storage
- Store at 2-8°C / 36-46°F
- Form
- Lyophilized Powder
Description
A peptide analog under investigation for metabolic regulation and energy homeostasis research.
Compound Guide
What is Retatrutide?
Triple-Agonist Metabolic Research
Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The addition of glucagon-receptor activity distinguishes it from dual agonists: alongside appetite and insulin signaling, it engages pathways associated with hepatic fat mobilization and energy expenditure.
Areas of Research Interest
Summarized from published research findings. Not medical guidance or prescribing information.
Energy Expenditure
Glucagon-receptor activity is studied for increased basal metabolic output, not just intake reduction.
Glycemic Endpoints
GLP-1 and GIP agonism are examined for glucose-dependent insulin response.
Gastric Transit
Delayed gastric emptying is a well-documented mechanism in this receptor class.
Appetite Signaling
Central satiety pathways are the primary studied endpoint for GLP-1 agonists.
Hepatic Fat Models
Glucagon-arm research includes liver-fat-fraction measures.
Titration-Dependent
Study designs universally use slow dose escalation to manage tolerability.
Reconstitution
- 5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL
- 10 mg vial + 2 mL bacteriostatic water = 5.0 mg/mL
- At 2.5 mg/mL, 1 unit on a U-100 syringe = 25 mcg
Suggested research protocol
- Route studied: subcutaneous, once weekly.
- Titration: hold each step at least 4 weeks before escalating.
- Never compress the titration schedule — tolerability findings are dose-rate dependent.
- Refrigerate; use within 30 days of reconstitution.
Dosing Reference
| Step | Weekly dose | U-100 units @ 2.5 mg/mL |
|---|---|---|
| Weeks 1–4 | 1 mg | 40 units |
| Weeks 5–8 | 2 mg | 80 units |
| Weeks 9–12 | 4 mg | 2 × 80 units |
| Weeks 13+ | 6–8 mg | Per protocol design |
Handling & Notes
- Gastrointestinal observations are the most frequently logged; they track with escalation rate.
- Adequate hydration and protein intake are standard controls in study design.
- Lean-mass endpoints are commonly co-measured alongside total-mass change.
Stack Up
Compounds studied alongside Retatrutide
This guide is provided for informational and research reference only. Retatrutide is intended for laboratory research use exclusively and is not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary consumption.